Eating slowly and stopping as soon as you feel comfortably full may also reduce digestive discomfort
Most cases are mild to moderate, appearing during weeks 26 of therapy as your body adjusts to appetite suppression and weight loss
Semaglutide is associated with a modest increase in gallbladder disease risk beyond that attributable to weight loss alone, with cholelithiasis reported in 1.62.5% vs 0.71.0% and cholecystitis in 0.6% vs 0.2% of Wegovy vs placebotreated adults in weightmanagement trials, and higher rates in adolescents
Tolerability: If you experienced significant nausea on one drug, the other may be worth trying after medical advice and careful titration
These include brown rice, farro, oats, and quinoa
Hair loss affects some people on GLP-1 agonists